

No: 25-1331V  
 39. Julian J. Miller, Milwaukee, Wisconsin, Court of Federal Claims No: 25-1332V  
 40. Melissa Trepanier, Gorham, Maine, Court of Federal Claims No: 25-1334V  
 41. Vivian Shellmire-Archedale, Dallas, Georgia, Court of Federal Claims No: 25-1335V  
 42. Jessica Fermin on behalf of E.F., East Windsor, Connecticut, Court of Federal Claims No: 25-1341V  
 43. James Fleenor, Salem, Indiana, Court of Federal Claims No: 25-1342V  
 44. Emily Pasman on behalf of J.P., Washington, DC, Court of Federal Claims No: 25-1343V  
 45. Nicole Caton, Washington, DC, Court of Federal Claims No: 25-1347V  
 46. Wilma Jones, Chicago, Illinois, Court of Federal Claims No: 25-1348V  
 47. Katherine Gastian, Rio Rancho, New Mexico, Court of Federal Claims No: 25-1350V  
 48. Paulette Crawford, Washington, DC, Court of Federal Claims No: 25-1351V  
 49. John Lauer, Washington, DC, Court of Federal Claims No: 25-1352V  
 50. James Michael Jackson, Louisville, Kentucky, Court of Federal Claims No: 25-1354V  
 51. Correna Andrews, Boston, Massachusetts, Court of Federal Claims No: 25-1355V  
 52. Courtney Kyle, Greenville, South Carolina, Court of Federal Claims No: 25-1356V  
 53. Dana Brison, Chesterfield, Missouri, Court of Federal Claims No: 25-1357V  
 54. La Toya Phillips-Blakeney, Washington, DC, Court of Federal Claims No: 25-1360V  
 55. Bobby De Johnette, Washington, DC, Court of Federal Claims No: 25-1361V  
 56. Linda Dickerson, Buffalo, New York, Court of Federal Claims No: 25-1364V  
 57. Kathleen Lucas, Dresher, Pennsylvania, Court of Federal Claims No: 25-1366V  
 58. Dorothy Stokes, Evans, Georgia, Court of Federal Claims No: 25-1368V  
 59. David Rodgers, Philadelphia, Pennsylvania, Court of Federal Claims No: 25-1369V  
 60. Davonci S. Hennings, Milwaukee, Wisconsin, Court of Federal Claims No: 25-1371V  
 61. Shirley Dishman, Dresher, Pennsylvania, Court of Federal Claims No: 25-1373V  
 62. Vance Smith, Brookfield, Wisconsin, Court of Federal Claims No: 25-1375V  
 63. Danielle Zacharski, Dresher, Pennsylvania, Court of Federal Claims No: 25-1379V  
 64. Morris Mester, San Diego, California, Court of Federal Claims No: 25-1381V  
 65. Surveen Klein, Jefferson, Louisiana, Court of Federal Claims No: 25-1386V  
 66. Angetta Michelle Petit, Marlton, New Jersey, Court of Federal Claims No: 25-1387V  
 67. Delfina Garcia, Boston, Massachusetts, Court of Federal Claims No: 25-1388V  
 68. Robert Hetterich, Bradenton, Florida, Court of Federal Claims No: 25-1390V  
 69. Holly Pacelli, Apple Valley, California, Court of Federal Claims No: 25-1391V  
 70. Chukwuma Marcellus Eleodimuo, Los Angeles, California, Court of Federal

Claims No: 25-1392V  
 71. Karen Steinig, Fishkill, New York, Court of Federal Claims No: 25-1393V  
 72. Casey B. Russell and Amanda N. Russell on behalf of E.G.R., Lewisburg, West Virginia, Court of Federal Claims No: 25-1396V  
 73. Susan Thompson, Chesapeake, Virginia, Court of Federal Claims No: 25-1400V  
 74. John Whyte Pennington, Greeley, Colorado, Court of Federal Claims No: 25-1401V  
 75. Catherine Nownes-Whitaker, Washington, DC, Court of Federal Claims No: 25-1402V  
 76. Marion Timmons, Wilmington, Delaware, Court of Federal Claims No: 25-1403V  
 77. Tene Griffin, Midlothian, Virginia, Court of Federal Claims No: 25-1404V  
 78. Allyson Kameid, Washington, DC, Court of Federal Claims No: 25-1405V  
 79. Nicole Fetterman, Washington, DC, Court of Federal Claims No: 25-1407V  
 80. Sian Haffner, Washington, DC, Court of Federal Claims No: 25-1408V  
 81. Andrea Daye, Washington, DC, Court of Federal Claims No: 25-1409V  
 82. Alisha Womack, Toms River, New Jersey, Court of Federal Claims No: 25-1412V  
 83. Rebecca J. Poynter, Greensboro, North Carolina, Court of Federal Claims No: 25-1415V  
 84. Rhett Whitley, Birmingham, Alabama, Court of Federal Claims No: 25-1416V  
 85. Amanda Lewis, Huntsville, Alabama, Court of Federal Claims No: 25-1419V  
 86. Maureen Wanty on behalf of the estate of Loretta Flanagan, Dresher, Pennsylvania, Court of Federal Claims No: 25-1421V  
 87. Kathleen Kormondy, Hilton Head, South Carolina, Court of Federal Claims No: 25-1422V  
 88. Perry Lavelle Washington, Clovis, California, Court of Federal Claims No: 25-1424V  
 89. Sejal Gowda, Athens, Georgia, Court of Federal Claims No: 25-1429V  
 90. Kimberly Hancock, Winston-Salem, North Carolina, Court of Federal Claims No: 25-1430V  
 91. Melissa Gaudet, Marrero, Louisiana, Court of Federal Claims No: 25-1434V  
 92. Sara Detweiler, Denver, Colorado, Court of Federal Claims No: 25-1435V  
 93. Christina Carter, Dresher, Pennsylvania, Court of Federal Claims No: 25-1436V  
 94. Nihaya Semrin, St. Louis Park, Minnesota, Court of Federal Claims No: 25-1437V  
 95. Kevin William Cassaday, Hope, Minnesota, Court of Federal Claims No: 25-1438V  
 96. Joan Budington, Yorkshire, New York, Court of Federal Claims No: 25-1440V  
 97. Peggy Dodds, Enterprise, Alabama, Court of Federal Claims No: 25-1445V  
 98. Christopher Walden, Olathe, Kansas, Court of Federal Claims No: 25-1446V  
 99. David Soetaert, Dresher, Pennsylvania, Court of Federal Claims No: 25-1447V  
 100. Shaylagh R. Dehney, Dracut, Massachusetts, Court of Federal Claims No: 25-1448V  
 101. Emma Nicole Hahesy, Brunswick, Maine, Court of Federal Claims No: 25-1449V

102. Richard Trala, Boston, Massachusetts, Court of Federal Claims No: 25-1450V  
 103. Nikolas Raw, Boston, Massachusetts, Court of Federal Claims No: 25-1451V  
 104. Charles Terrio III, Cromwell, Connecticut, Court of Federal Claims No: 25-1452V  
 105. Lori LaQuerre, Essex, Vermont, Court of Federal Claims No: 25-1453V  
 106. Gregory Atwater, Madison, Wisconsin, Court of Federal Claims No: 25-1454V

[FR Doc. 2025-18696 Filed 9-25-25; 8:45 am]

BILLING CODE 4165-15-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; NLM Information Resource Grants to Reduce Health Disparities and Promote Health for All.

*Date:* November 5, 2025.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Archana Jha, Ph.D., Scientific Review Officer, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 6701 Democracy Boulevard (1 Dem Plaza), Bethesda, MD 20892, (301) 480-2159, archana.jha@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Health Services and Systems B.

*Date:* November 13-14, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Sandhya Sanghi, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National

Institutes of Health, 5601 Fishers Lane, Suite 8B, Rockville, MD 20892, (301) 496-2879, sandhya.sanghi@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Bioanalytical, Molecular, Cellular Sciences and Technologies.

*Date:* November 14, 2025.

*Time:* 9:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Joonil Seog, SCD Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-402-9791, joonil.seog@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Drug Development, Resistance, and Therapeutics.

*Date:* November 18-19, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Robert C. Unfer, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3F40A, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892-9834, (240) 669-5035, robert.unfer@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Virology.

*Date:* November 19, 2025.

*Time:* 11:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Yong Gao, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G13B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9834, Rockville, MD 20892-9834, (240) 669-5048, yong.gao@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics on Transmission of Vector-Borne and Zoonotic Diseases.

*Date:* November 25, 2025.

*Time:* 9:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Liangbiao Zheng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD 20892, 301-996-5819, zhengli@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Visual, Memory, and Circuit Neuroscience.

*Date:* November 25, 2025.

*Time:* 10:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Nesar Uddin Akanda, Ph.D., Scientific Review Officer, SRB Scientific Review Branch, National Institute on Aging, 5601 Fishers Lane, Suite 8B, Rockville, MD 20892, (301) 594-8984, nesar.akanda@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Research for Women, Children, Pregnant and Lactating Women.

*Date:* December 1, 2025.

*Time:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Marilyn Moore-Hoon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-9295, mooremar@mail.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Microbial Diagnostics and Detection.

*Date:* December 3-4, 2025.

*Time:* 9:30 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Shinako Takada, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-827-5997, shinako.takada@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business Innovative Immunology and Vaccine Development.

*Date:* December 4-5, 2025.

*Time:* 10:00 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Dayadevi Jirage, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4422, Bethesda, MD 20892, (301) 867-5309, jiragedb@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR-24-174: Global Infectious Disease Research Training Program.

*Date:* December 9, 2025.

*Time:* 9:30 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Liangbiao Zheng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD 20892, 301-996-5819, zhengli@csr.nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Anti-infective therapeutics, diagnostic immunology, and decontamination.

*Date:* December 9-10, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Samita Sarkar Andreansky, Scientific Review Officer, NIAID AIDS Review Branch, BG 5601, Fishers Lane, Room 3E71, MSC 9834, 5601 Fishers Lane, Bethesda, MD 20892, (240) 669-2915, samita.andreansky@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business—Anti-infective Therapeutics.

*Date:* December 10-11, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Hailey P. Weerts, Ph.D., Scientific Review Officer, BG 5601 Fishers Lane, Room 3G74, 5601 Fishers Lane, Rockville, MD 20852, (240) 669-5931, hailey.weerts@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Infectious Disease Diagnostics, Pathogenesis, and Interactions.

*Date:* December 15, 2025.

*Time:* 2:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Jennifer Hartt Meyers, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9823, Rockville, MD 20852, 301-761-6602, jennifer.meyers@nih.gov.

Registration is not required to attend this meeting.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 23, 2025.

**Rosalind M. Niamke,**  
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-18691 Filed 9-25-25; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary & Integrative Health; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Complementary and Integrative Health.

*The meeting will be held as a virtual meeting and will be open to the public as indicated below.* Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. Once available, the open session meeting link can be accessed at the Institute's/Center's home page: <https://nccih.nih.gov/about/naccih>.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Complementary and Integrative Health.

*Date:* January 23, 2026.

*Closed:* 10:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, DEM 2, Suite 401, 6707 Democracy Boulevard, Bethesda, MD 20892, Virtual Meeting.

*Open:* 12:30 p.m. to 5:00 p.m.

*Agenda:* Reports and Updates about Recent and Ongoing NCCIH Led or Involved Activities by NCCIH staff and its Director.

*Address:* National Institutes of Health, DEM 2, Suite 401, 6707 Democracy Boulevard, Bethesda, MD 20892, Virtual Meeting.

*Contact Person:* Martina Schmidt, Ph.D., Director, Division of Extramural Activities, National Center for Complementary & Integrative Health, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 594-3456, [schmidma@mail.nih.gov](mailto:schmidma@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should be less than 700 words in length, and should include the name, email address, telephone number and when applicable, the business or professional affiliation of the interested person. *Any member of the public may submit written comments no later than January 9th, 2026 (14 days before the council meeting).*

Information is also available on the Institute's/Center's home page: <https://nccih.nih.gov/about/naccih>, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: September 24, 2025.

**Bruce A. George,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-18720 Filed 9-25-25; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Advocate Aurora Research Institute, located in Milwaukee, Wisconsin, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before October 14, 2025 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Elizabeth Pitts, Senior Technology Transfer and Patent Specialist, Technology Transfer and Intellectual Property Office, National

Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone number 301-669-5299, or [Elizabeth.pitts@nih.gov](mailto:Elizabeth.pitts@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following represents the intellectual property to be licensed under the prospective agreement: United States Provisional Patent Application Number 63/607,147, filed December 7, 2023, entitled "Zika Viruses and Uses Thereof" (HHS Reference No. E-137-2025-0-US-01) and PCT Patent Application Number PCT/US2024/058992, filed December 7, 2024, entitled "Zika Viruses and Uses Thereof" (HHS Reference No. E-137-2025-0-PCT-02).

The patent rights in these inventions have been assigned and/or exclusively licensed to Advocate Aurora Research Institute and Government of the United States of America as represented by the Secretary, Department of Health & Human Services.

The prospective patent license will be for the purpose of consolidating the patent rights to Advocate Aurora Research Institute, the co-owners of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212.

The prospective interinstitutional agreement will include an exclusive license for the National Institute of Allergy and Infectious Diseases' rights in these jointly owned patents. It will be sublicensable, and any sublicenses granted by Advocate Aurora Research Institute will be subject to the provisions of 37 CFR part 404.

Glioblastoma multiforme (GBM) is an aggressive, malignant brain cancer with poor prognosis under the current standard of care. Oncolytic viruses have potential as novel therapeutics for the treatment of GBM. The current technology, developed by Stephen Whitehead, Ph.D. from the National Institute of Allergy and Infectious Diseases and researchers at Advocate Aurora Research Institute, describes the use of Zika virus strains as an oncolytic virus for the treatment of GBM and other cancers.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Institute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant